This study is testing a new oral medication called RO7656594 for men with advanced or metastatic prostate cancer. Researchers want to understand how safe RO7656594 is, how your body handles it (pharmacokinetics), and if it shows any signs of working against the cancer. They also aim to find the best dose for future studies. You may be able to join if you have metastatic prostate cancer that has already been treated with certain hormone therapies (like abiraterone or enzalutamide). The study will look at side effects and any dose-limiting toxicities (serious side effects that prevent further treatment) to determine its success.

Study design

This is an interventional study planning to enroll 210 men. The phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

You will be monitored for adverse events from the start of treatment until 28 days after your last dose, for up to approximately 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.